Xifaxan He denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for xifaxan he are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a Not-FDA-Approved Denial

This denial type for rifaximin (Xifaxan) used for hepatic encephalopathy (HE) is factually contestable on its face. Rifaximin carries FDA approval for the HE indication, and a "not-FDA-approved" denial in this context is almost always a coding or policy-application error — either the prior authorization request was submitted under a code that does not map cleanly to the approved indication, or Cigna's system misclassified the clinical scenario.

It is also possible the denial refers to an off-label use pattern in the submission (for example, a dose, duration, or combination not reflected in the approved labeling) rather than to the drug itself. Understanding exactly which aspect Cigna is calling unapproved is the first step in building your appeal.

## Why This Is Appealable

• Factual error: If rifaximin is being used for its FDA-approved HE indication, the denial rests on a factual mistake. Appeals that correct a factual error in the insurer's record are among the fastest to resolve.
• ACA §2719 external review: If the internal appeal does not resolve the error, an independent external reviewer will evaluate the clinical and regulatory facts without deference to Cigna's initial determination. You generally have approximately four months from the denial notice; verify the exact deadline on your EOB.
• ERISA §503: Your plan must supply the specific basis for the not-approved classification, allowing you to rebut it point by point.
• Expedited review: Request expedited processing if delay would seriously harm your health.

## Documentation to Gather

• FDA label / prescribing information: Download the current rifaximin label from DailyMed (dailymed.nlm.nih.gov). Attach it to your appeal and highlight the HE indication section, approval date, and the specific patient population described.
• Prescriber attestation of on-label use: Your physician should confirm in writing that the prescribed use matches the FDA-approved indication and explain how your clinical presentation corresponds to the approved patient population described in the label.
• Diagnosis records: Chart documentation confirming your HE diagnosis and the clinical context that aligns with the approved indication.
• Denial letter analysis: Read Cigna's denial letter carefully to identify exactly which aspect they called unapproved. Address that specific claim in your appeal rather than writing a general rebuttal.

## Criteria-Mapping Approach

Obtain Cigna's coverage policy for rifaximin and locate the language describing the FDA-approval requirement. Place the relevant FDA label text alongside that policy language. Then add your prescriber's confirmation that your prescribed use falls within that approved scope. This three-column structure — policy requirement / FDA label / physician confirmation — is the clearest possible rebuttal to a not-approved denial.